Blood Inflammation Markers Track Gut Microbe Loss and Predict Sepsis Survival

Sepsis remains one of the most lethal conditions treated in intensive care units, and clinicians still lack reliable tools to predict which patients will survive the first month after diagnosis. A new prospective cohort study now reports that four circulating inflammatory molecules—monocyte chemoattractant protein-1 (MCP-1), growth differentiation factor-15 (GDF-15), proprotein convertase subtilisin/kexin type 9 (PCSK9), and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3)—are linked both to the depletion of beneficial gut bacteria and to 28-day mortality in septic patients. The findings, published in BMC Gastroenterology, suggest that measuring these biomarkers alongside routine clinical variables could sharpen risk stratification, although the authors caution that external validation in larger, ethnically diverse cohorts is required before any clinical use.

The research, led by Chenhui Zhang, Haiyan Lu, and Zhongshun Feng, enrolled 215 adults who met the Sepsis-3 criteria at a single center. Among these patients, 52 developed septic shock and 61 died within 28 days. The team measured serum concentrations of the four biomarkers using enzyme-linked immunosorbent assay and quantified fecal abundance of three bacterial genera—Escherichia coli, Bifidobacterium, and Lactobacillus—by absolute real-time polymerase chain reaction. The choice of Bifidobacterium and Lactobacillus reflects their established role as short-chain fatty acid-producing commensals that have previously been associated with systemic inflammation in sepsis.

The central observation was strikingly consistent across the cohort. All four biomarkers were elevated in patients with septic shock and in those who did not survive, while Bifidobacterium and Lactobacillus were reduced in the same groups, with all comparisons reaching statistical significance at P < 0.05. Each biomarker also correlated inversely with the abundance of both protective genera, with Spearman correlation coefficients ranging from −0.31 to −0.46 and all P values below 0.001. These inverse associations persisted when the investigators performed stratified and partial-correlation analyses, indicating that the relationship between circulating inflammation markers and gut commensal depletion was not an artifact of a single statistical approach.

To move beyond correlation and toward predictive utility, the researchers applied multivariable logistic regression adjusted for age, Sequential Organ Failure Assessment (SOFA) score, and lactate—a combination that accounts for some of the most powerful conventional predictors of outcome. After this adjustment, each of the four biomarkers remained independently associated with 28-day mortality. Conversely, higher abundance of Bifidobacterium and Lactobacillus was associated with lower 28-day mortality, reinforcing the idea that preservation of these commensal genera tracks with better survival independent of established severity measures.

The most technically ambitious part of the study involved testing whether the four-biomarker panel could outperform any single marker in discriminating survivors from non-survivors. Using receiver operating characteristic analysis, the panel achieved an area under the curve of 0.917, significantly better than any individual biomarker according to DeLong comparison (P < 0.001). At an internally derived cut-off, the panel showed an apparent sensitivity of 86.9% and specificity of 81.8%. When the investigators added routine clinical variables to the biomarker panel, the AUC rose to 0.954, with a bootstrap-corrected estimate of 0.943 after 1,000 resamples in which the entire model-fitting process was repeated. The optimism-corrected calibration slope was 0.86 and the Brier score was 0.078, indicating that the model’s predicted probabilities remained reasonably well aligned with observed outcomes despite some shrinkage after correction for overfitting.

Discrimination was preserved across subgroups defined by antibiotic exposure and by the timing of sample collection, suggesting that the biomarker-microbe relationship is robust to two common sources of variation in critically ill patients. This subgroup stability matters because antibiotics are known to alter gut microbiota, and because biomarker concentrations can fluctuate depending on when blood and stool samples are drawn relative to the onset of sepsis.

The biological rationale behind the study rests on the idea that intestinal dysbiosis—particularly the loss of short-chain fatty acid-producing commensals—contributes to the systemic inflammation that drives organ failure in sepsis. MCP-1 is a chemokine that recruits monocytes to sites of inflammation, GDF-15 is a stress-responsive member of the transforming growth factor-beta superfamily, PCSK9 is best known for its role in cholesterol metabolism but has emerging inflammatory functions, and NLRP3 is an inflammasome component that activates interleukin-1beta release. The study does not establish that any of these molecules cause microbial depletion or mortality; it demonstrates associations that survived multivariable adjustment and internal validation.

The authors are explicit about the limitations of their work. As a prospective single-center cohort, the study captured a specific population and cannot be generalized without replication. The statistical approach included bootstrap internal validation with 1,000 samples, in which the full model-fitting process was repeated in each resample, but this addresses only apparent optimism, not external generalizability. The conclusion states that the integrated inflammatory-microbial approach to sepsis risk stratification requires external validation in multicentre, ethnically diverse cohorts before any clinical implementation. The clinical trial registration field notes that trial registration was not applicable, consistent with the observational design.

What the study offers, within those boundaries, is a quantified link between a specific set of circulating inflammatory mediators and the depletion of two genera of gut commensals that have been repeatedly implicated in sepsis biology. The four-biomarker panel, especially when combined with age, SOFA score, and lactate, achieved discrimination that was internally validated with modest optimism. Whether this translates into a clinically useful tool will depend on whether independent teams, working with different patient populations and different laboratory platforms, can reproduce the same associations and the same predictive performance. Until then, the findings stand as a detailed observational map of how systemic inflammation and gut microbial composition move together in sepsis—and as a hypothesis-generating foundation for future multicentre validation studies.

Subject of Research: Prospective cohort study examining associations between serum inflammatory biomarkers and gut commensal abundance with 28-day mortality in sepsis.

Article Title: Associations of serum MCP-1, GDF-15, PCSK9, and NLRP3 with fecal Bifidobacterium and Lactobacillus abundance and 28-day mortality in sepsis: a prospective single-center cohort study

Article References: Zhang, C., Lu, H., & Feng, Z. (2026). Associations of serum MCP-1, GDF-15, PCSK9, and NLRP3 with fecal Bifidobacterium and Lactobacillus abundance and 28-day mortality in sepsis: a prospective single-center cohort study. BMC Gastroenterology. https://doi.org/10.1186/s12876-026-05487-w

Image Credits: AI Generated

DOI: 10.1186/s12876-026-05487-w

Keywords: sepsis, MCP-1, GDF-15, PCSK9, NLRP3, Bifidobacterium, Lactobacillus, gut microbiota, biomarker panel, 28-day mortality, risk stratification, intestinal dysbiosis